Navigation Links
Corgenix Reports Financial Results for First Quarter of Fiscal 2009
Date:11/13/2008

DENVER, Nov. 13 /PRNewswire-FirstCall/ -- Corgenix Medical Corporation (OTC Bulletin Board: CONX), a worldwide developer and marketer of diagnostic test kits, reported sales of $2,001,896 for the first fiscal quarter ended September 30, 2008, compared with $2,105,188 for the quarter ended September 30, 2007, a decrease of 4.9%. Excluding revenues from contract manufacturing, Corgenix sales increased 9.6% over the same period in the prior fiscal year.

The first quarter of fiscal 2009 produced an operating loss of $94,133 compared with operating income of $2,023 for the first quarter of fiscal 2008. The net loss for the quarter was $340,659 or $0.01 per share, compared to a net loss of $688,129, or $0.04 per share, in the year earlier quarter. The primary causes of the reduced net loss for the current quarter were the reductions in the cost of sales as a percentage of sales from 45.8% in the previous year to 44.6% in the current quarter, in addition to the reduced interest expense, from $680,324 in the prior year to $252,611 in the current quarter.

During the first quarter of fiscal 2009, Corgenix was again named one of Colorado's 50 fastest growing technology companies in Colorado in a list compiled by Deloitte & Touche.

"During the quarter, we saw solid growth in sales of most Corgenix products and were successful in cutting our quarterly net loss in half," said Douglass Simpson, Corgenix President and CEO. "The decrease in total revenue was mainly due to the loss of some contract manufacturing business, but we remain optimistic that we will replace that part of our business later this year with some exciting new strategic alliances."

Mr. Simpson added, "We believe the remainder of this fiscal year will begin to reflect a number of additional accomplishments including the efforts we continue to put forth in growing our AspirinWorks business."

First Quarter Fiscal 2009 Conference Call Details

Corgenix invites all those interested in hearing management's discussion of fiscal year results to join a shareholders conference call on Thursday, November 13, 2008, at 4:00 PM EST (2:00 PM MST). Interested parties can join the call by dialing (800) 895-0198. International participants may access the call by dialing +1 785 424 1053. The conference code is "CORGENIX." A replay will be available for 30 days following the call by dialing (800) 723-0544 for U.S. participants and +1 402 220 2656 for international participants.

About Corgenix Medical Corporation

Corgenix is a leader in the development and manufacturing of specialized diagnostic kits for immunology disorders, vascular diseases and bone and joint disorders, including the world's only non-blood-based test for aspirin effect. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 50 diagnostic products through a global distribution network and has significant experience advancing products through the FDA process. More information is available at http://www.corgenix.com.

Statements in this press release that are not strictly historical facts are "forward looking" statements (identified by the words "believe", "estimate", "project", "expect" or similar expressions) within the meaning of the Private Securities Litigation Reform Act of 1995. These statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company's products and services in the marketplace, competitive factors, changes in the regulatory environment, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. The statements in this press release are made as of today, based upon information currently known to management, and the company does not undertake any obligation to publicly update or revise any forward-looking statements.

SUMMARY OF FINANCIAL HIGHLIGHTS

($000 of U.S. dollars except shares outstanding and per share amounts)

CORGENIX MEDICAL CORPORATION AND SUBSIDIARIES

OPERATIONAL DATA

Quarter Ended September 30

2008 2007

Net sales $2,002 $2,105

Gross profit 1,107 1,149

Operating income (loss) (94) 2

Net loss (341) (688)

Basic and diluted loss

per share $(0.01) $(0.04)

Basic and Diluted shares

outstanding 30,092,093 19,340,384

BALANCE SHEET DATA

September 30, 2008 June 30, 2008

Cash $1,023 $1,520

Working capital 2,513 2,889

Total assets 7,337 7,888

Long-term debt 1,129 1,276

Total stockholders' equity 3,886 4,153


'/>"/>
SOURCE Corgenix Medical Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Corgenix Announces Expansion of Hemorrhagic Fever Virus Product Development Program
2. Corgenix Reports Third Quarter Fiscal 2008 Financial Results
3. Corgenix to Exhibit AspirinWorks(R) Test at 2008 ACOFP Meeting in Denver
4. MiddleBrook Pharmaceuticals Reports Third Quarter 2008 Financial Results
5. Spheris Reports Third Quarter 2008 Results
6. MAP Pharmaceuticals Reports Third Quarter of 2008 Financial Results
7. Symmetry Medical Reports Third Quarter 2008 Financial Results
8. EntreMed Reports Clinical Program Progress and Company Update
9. NBTY Reports Fourth Quarter and Fiscal Year Results
10. IPC The Hospitalist Company Reports Record Third Quarter 2008 Results
11. Consumer Reports Survey: Nearly Half of Adults Wont Get Flu Vaccine, Citing Poor Excuses Like I Dont Get Sick
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... (PRWEB) , ... January 17, 2017 , ... Recently, patients ... in Southwest Michigan, joined other volunteers and organizations in support of the annual Binder ... children and families dressed up in colorful costumes of all designs coming out to ...
(Date:1/16/2017)... (PRWEB) , ... January 16, 2017 , ... ... products, will demonstrate their groundbreaking GunSport•PRO® and EB15•LE® electronic earplugs at the NSSF ... in Las Vegas, Booth #2809. The SHOT Show is the shooting, hunting and ...
(Date:1/16/2017)... ... January 16, 2017 , ... Houston dentist, ... is currently offering complimentary consultations and financing for orthodontics for a limited time. ... irregularities and learn about their orthodontic options. Walk-in, late-evening, Saturday, and same-day appointments ...
(Date:1/16/2017)... ... 2017 , ... Specialty Technical Publishers (STP) and Specialty Technical ... (IAPC) EHS audit protocol for Singapore . Leading companies around the world ... obligations and rapidly collect, share, archive, and export audit findings in a cost ...
(Date:1/16/2017)... ... January 16, 2017 , ... Date aired: ... http://www.ageofautism.com/legal , Sharon Kleyne, America’s leading water educator, researcher and advocate welcomed ... radio program, The Sharon Kleyne Hour Power of Water, Global Climate Change and ...
Breaking Medicine News(10 mins):
(Date:1/17/2017)... , Jan 17, 2017 Research and ... Market 2016-2020" report to their offering. ... The global laparotomy sponges market to ... Global Laparotomy Sponges Market 2016-2020, has been prepared ... The report covers the market landscape and its growth prospects over ...
(Date:1/17/2017)...  ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ... Quinn Ph.D as Vice President Corticotropin Regulatory Affairs, ... Karen Quinn is a professional with over ... Affairs, specifically with a focus on drug products ... most recently with Takeda Pharmaceuticals International as Senior ...
(Date:1/17/2017)... , Jan. 17, 2017  Bayer today announced the appointment ... Pharmaceuticals business in the Americas, comprising the United ... Latin America . In this role, Dr. ... the Board of Management of Bayer AG and President of ... highly respected leader in the pharmaceutical industry and I,m delighted ...
Breaking Medicine Technology: